Keep an Eye on Biogen, Johnson & Johnson, and Merck Today
Biogen, Johnson & Johnson, and Merck could all make health care headlines this morning. Here’s all the news you need to know.
FDA Takes Issue with Takeda's Prospective 2014 Approval of Vedolizumab
Concerns over infection risks spurred action from an FDA advisory panel regarding the approval of the inflammatory bowel disease treatment vedolizumab.
1 ETF Every Investor Should Own
A Fool's guide to beating the market.